Walleye Capital’s AbCellera Biologics ABCL Stock Holding History

Walleye Capital’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$71	Sell	9 -9,771	-100%	-$47.8K	﹤0.01%	4648
2026 Q1	$34.1K	Sell	9,780 -239,270	-96%	-$861K	﹤0.01%	3986
2025 Q4	$852K	Buy	+249,050	New	+$1.11M	﹤0.01%	2569
2025 Q1	–	Sell	-15,000	Closed	-$44K	–	4158
2024 Q4	$44K	Sell	15,000 -241,881	-94%	-$674K	﹤0.01%	4383
2024 Q3	$668K	Buy	+256,881	New	+$712K	﹤0.01%	3032
2023 Q3	–	Sell	-1,059	Closed	-$6.44K	–	4798
2023 Q2	$6.84K	Buy	+1,059	New	+$7.23K	﹤0.01%	3975
2021 Q2	–	Sell	-10,593	Closed	-$360K	–	1314
2021 Q1	$360K	Buy	+10,593	New	+$422K	0.02%	699

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Walleye Capital's ABCL Position: Q2 2026 in Review

Walleye Capital reduced its AbCellera Biologics (ABCL) stake by 100% in Q2 2026, selling an estimated $47.8K and leaving 9 shares worth $71. The position accounts for ﹤0.01% of the portfolio, ranked #4648.

Walleye Capital first reported a position in ABCL in Q1 2021 and has held it in 7 quarters since. The position peaked at $852K in Q4 2025. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Walleye Capital held 9 shares of AbCellera Biologics worth $71 as of Q2 2026.
Walleye Capital sold 9,771 AbCellera Biologics shares in Q2 2026, an estimated $47.8K.
AbCellera Biologics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4648 holding.
Walleye Capital first reported a position in AbCellera Biologics in Q1 2021 and has held it in 7 quarters since.
Walleye Capital's AbCellera Biologics position peaked at $852K in Q4 2025.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.